DK1091729T3 - Mikropartikelformulering til inhalation - Google Patents

Mikropartikelformulering til inhalation

Info

Publication number
DK1091729T3
DK1091729T3 DK99928111T DK99928111T DK1091729T3 DK 1091729 T3 DK1091729 T3 DK 1091729T3 DK 99928111 T DK99928111 T DK 99928111T DK 99928111 T DK99928111 T DK 99928111T DK 1091729 T3 DK1091729 T3 DK 1091729T3
Authority
DK
Denmark
Prior art keywords
inhalation
microparticle formulation
agent
therapeutic
microparticles
Prior art date
Application number
DK99928111T
Other languages
English (en)
Inventor
Susan Stewart Smith
Stuart Robinson
Original Assignee
Quadrant Drug Delivery Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Quadrant Drug Delivery Ltd filed Critical Quadrant Drug Delivery Ltd
Application granted granted Critical
Publication of DK1091729T3 publication Critical patent/DK1091729T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A61K38/063—Glutathione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4826—Trypsin (3.4.21.4) Chymotrypsin (3.4.21.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1688—Processes resulting in pure drug agglomerate optionally containing up to 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK99928111T 1998-06-30 1999-06-28 Mikropartikelformulering til inhalation DK1091729T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9814172.4A GB9814172D0 (en) 1998-06-30 1998-06-30 Formulation for inhalation
PCT/GB1999/002023 WO2000000176A1 (en) 1998-06-30 1999-06-28 Microparticle formulation for inhalation

Publications (1)

Publication Number Publication Date
DK1091729T3 true DK1091729T3 (da) 2008-07-21

Family

ID=10834700

Family Applications (1)

Application Number Title Priority Date Filing Date
DK99928111T DK1091729T3 (da) 1998-06-30 1999-06-28 Mikropartikelformulering til inhalation

Country Status (14)

Country Link
EP (1) EP1091729B1 (da)
JP (1) JP2002519315A (da)
CN (1) CN1198582C (da)
AT (1) ATE390915T1 (da)
AU (1) AU752563B2 (da)
BR (1) BR9911697A (da)
CA (1) CA2336376C (da)
DE (1) DE69938452T2 (da)
DK (1) DK1091729T3 (da)
EA (1) EA200100088A1 (da)
ES (1) ES2303378T3 (da)
GB (1) GB9814172D0 (da)
IL (1) IL140306A0 (da)
WO (1) WO2000000176A1 (da)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0441380B1 (en) * 1990-02-08 1996-09-11 Canon Kabushiki Kaisha Image pick-up device
EP0877602B1 (de) 1996-01-24 2002-01-23 Byk Gulden Lomberg Chemische Fabrik GmbH Verfahren zur herstellung von pulverförmigen lungensurfactant-zubereitungen
US20060165606A1 (en) 1997-09-29 2006-07-27 Nektar Therapeutics Pulmonary delivery particles comprising water insoluble or crystalline active agents
US8771740B2 (en) * 1999-12-20 2014-07-08 Nicholas J. Kerkhof Process for producing nanoparticles by spray drying
US7871598B1 (en) 2000-05-10 2011-01-18 Novartis Ag Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use
WO2001087277A2 (en) * 2000-05-15 2001-11-22 Vectura Limited Method of manufacturing particles
GB0011807D0 (en) * 2000-05-16 2000-07-05 Quadrant Holdings Cambridge Formulation for inhalation
AU8111301A (en) * 2000-08-07 2002-02-18 Inhale Therapeutic Syst Inhaleable spray dried 4-helix bundle protein powders having minimized aggregation
US6805853B2 (en) 2001-11-09 2004-10-19 Alexza Molecular Delivery Corporation Delivery of diazepam through an inhalation route
US20070122353A1 (en) 2001-05-24 2007-05-31 Hale Ron L Drug condensation aerosols and kits
US6759029B2 (en) 2001-05-24 2004-07-06 Alexza Molecular Delivery Corporation Delivery of rizatriptan and zolmitriptan through an inhalation route
US20030051728A1 (en) 2001-06-05 2003-03-20 Lloyd Peter M. Method and device for delivering a physiologically active compound
CA2446904A1 (en) 2001-05-24 2003-04-03 Alexza Molecular Delivery Corporation Delivery of drug esters through an inhalation route
WO2002094218A2 (en) 2001-05-24 2002-11-28 Alexza Molecular Delivery Corporation Delivery of alprazolam, estazolam, midazolam or triazolam through an inhalation route
US20080026068A1 (en) * 2001-08-16 2008-01-31 Baxter Healthcare S.A. Pulmonary delivery of spherical insulin microparticles
AU2002363947A1 (en) 2001-11-21 2003-07-24 Alexza Molecular Delivery Corporation Delivery of caffeine through an inhalation route
TWI324518B (en) 2001-12-19 2010-05-11 Nektar Therapeutics Pulmonary delivery of aminoglycosides
US6900317B2 (en) 2002-02-19 2005-05-31 Boehringer Ingelheim Pharma Gmbh & Co. Kg Salts of the CGRP antagonist BIBN4096 and inhalable powdered medicaments containing them
US9339459B2 (en) 2003-04-24 2016-05-17 Nektar Therapeutics Particulate materials
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
CA2526475A1 (en) 2003-05-21 2004-12-02 Alexza Pharmaceuticals, Inc. Optically ignited or electrically ignited self-contained heating unit and drug-supply unit employing same
US7625865B2 (en) 2004-03-26 2009-12-01 Universita Degli Studi Di Parma Insulin highly respirable microparticles
ES2542146T3 (es) 2006-07-31 2015-07-31 Novo Nordisk A/S Insulinas extendidas PEGiladas.
WO2008034881A1 (en) 2006-09-22 2008-03-27 Novo Nordisk A/S Protease resistant insulin analogues
ES2594867T3 (es) 2007-03-09 2016-12-23 Alexza Pharmaceuticals, Inc. Unidad de calentamiento para usar en un dispositivo de administración de fármaco
US9387176B2 (en) 2007-04-30 2016-07-12 Novo Nordisk A/S Method for drying a protein composition, a dried protein composition and a pharmaceutical composition comprising the dried protein
JP2010534248A (ja) 2007-07-21 2010-11-04 アルバニー モレキュラー リサーチ， インコーポレイテッド ５−ピリジノン置換インダゾール
WO2009020434A1 (en) * 2007-08-07 2009-02-12 Nanomaterials Technology Pte Ltd A process for making micro-sized protein particles
EP2222639A1 (en) 2007-11-21 2010-09-01 Decode Genetics EHF Biaryl pde4 inhibitors for treating pulmonary and cardiovascular disorders
ES2523580T3 (es) 2008-01-11 2014-11-27 Albany Molecular Research, Inc. Piridoindoles substituidos con (1-Azinona)
WO2009112583A2 (en) 2008-03-14 2009-09-17 Novo Nordisk A/S Protease-stabilized insulin analogues
JP5749155B2 (ja) 2008-03-18 2015-07-15 ノボ・ノルデイスク・エー／エス プロテアーゼ安定化アシル化インスリンアナログ
WO2010059836A1 (en) 2008-11-20 2010-05-27 Decode Genetics Ehf Substituted aza-bridged bicyclics for cardiovascular and cns disease
RU2506266C2 (ru) 2009-01-26 2014-02-10 Израэл Инститьют Фо Байолоджикал Рисерч Бициклические гетероциклические спиросоединения
EP2410981B2 (en) 2009-03-26 2020-02-26 Pulmatrix Operating Company, Inc. Dry powder formulations and methods for treating pulmonary diseases
US8758824B2 (en) 2010-08-30 2014-06-24 Pulmatrix, Inc. Respirably dry powder comprising calcium lactate, sodium chloride and leucine
CN105640925B (zh) 2010-08-30 2019-08-16 普马特里克斯营业公司 干燥粉末配方及用于治疗肺部疾病的方法
KR101915241B1 (ko) 2010-09-29 2018-11-06 풀매트릭스 오퍼레이팅 컴퍼니, 인크 흡입용의 1가 금속 양이온 건조 분말
ES2899621T3 (es) 2010-09-29 2022-03-14 Pulmatrix Operating Co Inc Polvos secos catiónicos que comprenden sal de magnesio
MX2014012096A (es) 2012-04-11 2014-11-21 Novo Nordisk As Formulaciones de insulina.
EP3607941A1 (en) 2013-04-30 2020-02-12 Otitopic Inc. Dry powder formulations and methods of use
US9896496B2 (en) 2013-10-07 2018-02-20 Novo Nordisk A/S Derivative of an insulin analogue
CA2977083A1 (en) 2014-02-20 2015-08-27 Kambiz Yadidi Dry powder formulations for inhalation
KR102666667B1 (ko) 2014-07-31 2024-05-17 벡추라 인코포레이티드 흡입용 건조 분말 제형
ES2886837T3 (es) 2016-12-16 2021-12-21 Novo Nordisk As Composiciones farmacéuticas que contienen insulina
EP3768267A4 (en) 2018-03-20 2022-04-20 Icahn School of Medicine at Mount Sinai KINA INHIBITOR COMPOUNDS AND COMPOSITIONS AND METHODS OF USE
IT201800006336A1 (it) * 2018-06-14 2019-12-14 Glutatione ridotto in forma solida amorfa altamente solubile e processo per ottenerlo
KR20210042412A (ko) 2018-09-06 2021-04-19 주식회사 이노파마스크린 천식 또는 파킨슨병 치료를 위한 방법 및 조성물
CN113508111A (zh) 2018-12-31 2021-10-15 西奈山伊坎医学院 激酶抑制剂化合物和组合物及使用方法
US20230158125A1 (en) 2020-04-20 2023-05-25 Sorrento Therapeutics, Inc. Pulmonary Administration of ACE2 Polypeptides

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1227855B (de) * 1960-07-12 1966-11-03 Ichthyol Ges Verfahren zur Herstellung von Enzymkoerpern fuer die Durchfuehrung enzymatischer Reaktionen
DE1517787A1 (de) * 1965-12-06 1970-01-29 Takeda Chemical Industries Ltd Enzympraeparat und Verfahren zu seiner Herstellung
CS180896B1 (en) * 1975-07-22 1978-02-28 Pavel Veber Process for treatment of agents for releasing cells from fabrics and surface of cultivation vessels
US6063910A (en) * 1991-11-14 2000-05-16 The Trustees Of Princeton University Preparation of protein microparticles by supercritical fluid precipitation
US6582728B1 (en) * 1992-07-08 2003-06-24 Inhale Therapeutic Systems, Inc. Spray drying of macromolecules to produce inhaleable dry powders
EP0748225B1 (en) * 1994-03-04 2004-06-09 Genentech, Inc. PHARMACEUTICALLY ACCEPTABLE DNase FORMULATION
KR100419037B1 (ko) * 1994-03-07 2004-06-12 넥타르 테라퓨틱스 폐를통한인슐린의전달방법및그조성물

Also Published As

Publication number Publication date
JP2002519315A (ja) 2002-07-02
IL140306A0 (en) 2002-02-10
EP1091729A1 (en) 2001-04-18
CN1198582C (zh) 2005-04-27
DE69938452T2 (de) 2009-05-07
CN1317958A (zh) 2001-10-17
ATE390915T1 (de) 2008-04-15
CA2336376C (en) 2008-11-25
CA2336376A1 (en) 2000-01-06
EA200100088A1 (ru) 2001-06-25
EP1091729B1 (en) 2008-04-02
BR9911697A (pt) 2001-03-20
WO2000000176A1 (en) 2000-01-06
DE69938452D1 (de) 2008-05-15
AU752563B2 (en) 2002-09-19
GB9814172D0 (en) 1998-08-26
AU4523399A (en) 2000-01-17
ES2303378T3 (es) 2008-08-01

Similar Documents

Publication Publication Date Title
DK1091729T3 (da) Mikropartikelformulering til inhalation
AR018161A1 (es) Dispositivo para administrar un agente activo a los pulmones de un paciente humano
NZ524138A (en) Cyanophenoxy carboxylic acid compounds and compositions for delivering active agents
ID24901A (id) Metode pengobatan keadaan terkoagulasi tinggi atau defisiensi protein c yang diperoleh
MX353044B (es) Liberacion sostenida de anti-infecciosos.
NO20043871L (no) Legemiddelformuleringer med kontrollert frigjoring som inneholder et baererpeptid
WO2008013929A3 (en) Anti-migraine oral spray formulations and methods
RS54050B1 (en) FORMULATIONS AND METHODS FOR THE TREATMENT OF AMYLOIDOSIS
EA200501105A1 (ru) Фармацевтическая композиция
IL140848A0 (en) Treatment regimen for administration of phenylacetylacetylglutamine, phenylacetylisoglutamine and/or phenylacetate
NZ507203A (en) Use of dexmedetomidine for ICU sedation
BR0008713A (pt) Processos para preparar formulações ecomposições farmacêuticas orais com ecb
WO2002015876A3 (en) Amorphous carrier materials for drug delivery
AU2002332488A8 (en) R-bambuterol, its preparation and therapeutic uses
PL368686A1 (en) Novel aminobenzoephenones
MY136546A (en) A pharmaceutical component based on human parathyroid harmone and a pharmaceutical composition for intranasal administration comprising the component
MXPA02009603A (es) Terapias de dosis divididas con actividad de deterioro vascular.
WO2004033484A3 (en) Use of stable glutamine derivatives to improve drug absorption
EP1297838A4 (en) PRALMORELIN-CONTAINED NOSE DROP PREPARATIONS
GB0018322D0 (en) Pharmaceutical compositions
WO2001045727A3 (en) Stabilized veterinary compositions comprising more than one antiviral agent
JP2004538239A5 (da)
WO2001041771A3 (de) Acetylsalicylsäure enthaltendes transdermales system zur behandlung von migräne
BR0312333A (pt) Terapia de combinação e agente para sua execução
RU2000108989A (ru) Способ профилактики и лечения респираторных болезней телят